Shareholders that lost money on Keros Therapeutics, Inc. (KROS) should contact Levi & Korsinsky about Securities Fraud Investigation – KROS
NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the […]